Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors

BACKGROUND: The 2 somatostatin analogs currently recommended by the National Comprehensive Cancer Network for the treatment of gastrointestinal (GI) neuroendocrine tumors (NETs) include octreotide long-acting release (Sandostatin LAR) for injectable suspension and lanreotide (Somatuline Depot) injec...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am Health Drug Benefits
Main Authors: Ayyagari, Rajeev, Neary, Maureen, Li, Shang, Rokito, Ariel, Yang, Hongbo, Xie, Jipan, Benson, Al B.
Formato: Artigo
Idioma:Inglês
Publicado em: Engage Healthcare Communications, LLC 2017
Assuntos:
Business
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5726060/
https://ncbi.nlm.nih.gov/pubmed/29263774
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados